Business
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline’s pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential, for the treatment of cardiovascular diseases – – Transaction is expected to be completed in the fourth quarter of 2025, subject to customary closing conditions – NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio,
About this update from Novartis Ag
[{"type":"image","alt":"Tourmaline Bio, Inc.","displaySize":"","headline":null,"caption":"Tourmaline Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1280,"height":720,"url":"https://media.zenfs.com/en/globenewswire.com/8897a27290c6133695671002ab4536ac"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wZINn8DMK0J3H1cRHgGT1w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8897a27290c6133695671002ab4536ac","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/baAvCvdpEZeulPrvjDVSQw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/8897a27290c6133695671002ab4536ac","width":1200,"height":675}},"lazy":false},{"type":"text","content":"– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion –","length":122,"tagName":"p"},{"type":"text","content":"– Transaction reflects the potential of Tourmaline’s pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential, for the treatment of cardiovascular diseases –","length":200,"tagName":"p"},{"type":"text","content":"– Transaction is expected to be completed in the fourth quarter of 2025, subject to customary closing conditions –","length":114,"tagName":"p"},{"type":"text","content":"NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines that establish new standards of care for patients with life-altering inflammatory and immune diseases, today announced that it has entered into a merger agreement with Novartis AG (“Novartis”), pursuant to which Novartis will acquire Tourmaline for $48.00 per share in cash at closing, or a total equity value of approximately $1.4 billion. This represents a premium of 59% to Tourmaline’s closing stock price on September 8, 2025, the last trading day before the announcement of the transaction, and 127% to Tourmaline's 60-day volume-weighted average stock price as of that same date. The transaction has been unanimously approved by the Boards of Directors of both companies.","length":859,"tagName":"p"},{"type":"text","content":"“Our mission at Tourmaline has been to establish new standards of care in areas o...